Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share Price
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by mrv2000on Mar 24, 2021 1:39pm
235 Views
Post# 32867460

RE:Share Price

RE:Share Price
good.

smart money was buying at the end of jan - pre pop

ATE now has 70 million bukaroos more. on really great terms for  ATE.. that means smarter people sees a good risk reward profile 20 mill down, plus (for  asian market which is huge)
40 mill at 6.00... other smart money is likely looking at it, not brave enough to be the first ones

big money is just messing around when they can, or on market volitile days. shaking out the diamond hands that bought on the way up, that are in a bit of pain.....

theres not a big float now

this company has never looked better on future prospects.. dosnt mean its for sure succsessful.

nasdaq..... shmasdaq... dont care till its over 10.00 after the next deal or good results, then they can take it up...

what do i know.. i dont have a yacht

gla






<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities